7th April 2017 – Nottingham, UK – Sygnature Discovery has been ranked 906th in the Financial Times FT1000 .
The FT1000 lists the 1,000 companies in Europe that have achieved the highest percentage growth in revenues between 2012 and 2015.
As the Financial Times describes it, “Innovative and fast-growing companies are the driving force of the European economy in the 21st century. They generate jobs and sustain Europe’s competitiveness.”
Dr Paul J. Clewlow, Senior VP, Business Development, at Sygnature Discovery said, “It is a significant achievement for Sygnature Discovery to be included in the FT1000 and demonstrates the increasing demand that we are seeing for our integrated drug discovery know-how and expertise. There are only five other pharmaceutical companies in total in this list of Europe’s 1,000 fastest-growing companies and none are competitors of Sygnature Discovery.”
Sygnature Discovery, founded in Nottingham, UK, in 2004, has 180 full-time staff. 80% of the research scientists employed by Sygnature have PhDs. The company will begin its relocation to Discovery Building at BioCity Nottingham in late April 2017. Since 2011, nine drug candidates developed by Sygnature Discovery have entered clinical trials.